Navigation Links
Bacterin Secures $25 Million Financing with OrbiMed
Date:8/28/2012

orking with Guy and his team to help the company achieve its full potential," added Matthew Rizzo, also a Managing Director on the Royalty Opportunities team.  

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.  

About OrbiMed

OrbiMed is the world's largest healthcare-dedicated investment firm by net assets under management.  With approximately $6 billion under management, OrbiMed invests across the entire spectrum of pharmaceutical, biotechnology and medical device companies on a worldwide basis. Investments are made through private equity funds, public equity funds, royalty funds and other investment vehicles.

Since inception of its private investment activities in 1993, OrbiMed has invested in over 140 companies across a wide range of therapeutic categories and stages of development.  OrbiMed's investment team includes over 60 experienced professionals based in New York City, San
'/>"/>

SOURCE Bacterin International Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
2. Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year
3. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
4. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
5. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
6. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
7. Generex Secures Commitments for $3.6M Capital Raise
8. Roka Bioscience Secures $47.5 Million in Series D Financing
9. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
10. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
11. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:9/30/2014)... 2014 Applying a well-known optical phenomenon called ... University has demonstrated the ability to "paint" ultra-thin ... holds promise for making future, flexible electronic devices, ... of next-gen rocket ships and spacecraft with extremely ... oil in water, it becomes iridescent, revealing a ...
(Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
(Date:9/30/2014)... 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ... has received a Canadian Patent for Inhibition or ... patent includes claims using thymosin beta 4, various ... for these purposes.  The patent will expire in ... ( www.regenerx.com ) RegeneRx is ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Ind. - Researchers are edging toward the creation ... of ultra-efficient transmission of light, with potential applications ... The metamaterial - layers of silver and titanium ... dramatically changes the properties of light. The light ...
... CRANBURY, N.J., May 25, 2012  Oncobiologics, Inc. announced ... positions with established biopharmaceutical industry experts. Stephen J. ... and Vincent J. Benn, Ph.D. has joined the ... The company also announced its new Scientific Advisory ...
... ANAHEIM, Calif., May 24, 2012 Questcor Pharmaceuticals, Inc. (NASDAQ: ... present at the Jefferies 2012 Global Healthcare Conference in New ... 8:00 a.m. ET. A live webcast and subsequent ... http://ir.questcor.com/events.cfm .  The replay will be available for approximately 90 ...
Cached Biology Technology:'Metamaterials,' quantum dots show promise for new technologies 2Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board 2Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board 3Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference 2
(Date:9/30/2014)... the environmental effects of moorland burning is published today ... with the aim of relieving tensions on both sides ... EMBER (Effects of Moorland Burning on the Ecohydrology of ... moorland, which is practised predominantly to support red grouse ... peat hydrology, peat chemistry and physical properties, river water ...
(Date:9/30/2014)... The most comprehensive assessment conducted by the Ocean ... out of 100 in overall health. In addition, ... Antarctic and the 15 ocean regions beyond national ... maintaining a healthy climate, safeguarding biodiversity and providing ... update of the index, a partnership led by ...
(Date:9/30/2014)... Calif. The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama,s BRAIN (Brain Research ... research effort to revolutionize our understanding of the ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Rating the planet's oceans 2Rating the planet's oceans 3NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... (ODS) at the National Institutes of Health (NIH) announces ... Bibliography of Significant Advances in Dietary Supplement Research. The ... by government, industry, and academic institutions, as well as ... of laboratory, human studies, and observational studies in the ...
... powerful antioxidant in green tea may prevent or delay ... Georgia researchers say. Researchers were testing EGCG, green ... 1 diabetes and primary Sjogren,s syndrome, which damages moisture-producing ... study focused on Sjogren,s syndrome, so learning that EGCG ...
... Washington, DCGeorgetown University Medical Center and Oak ... between the institutions that formalizes their research ... researchparticularly in the areas of structural biology, ... biology. The Comprehensive Research and Development ...
Cached Biology News:Annual Bibliography of Significant Advances in Dietary Supplement Research 2007 2Green tea may delay onset of type 1 diabetes 2Green tea may delay onset of type 1 diabetes 3GUMC and Oak Ridge National Labs announce unique research partnership 2GUMC and Oak Ridge National Labs announce unique research partnership 3
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Anti-Natural Killer Cell Receptor-P1, clone ... Hybridoma produced by ... BALB/c mice immunized (BALB/c X ... cells and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Biology Products: